XNAS
PAVS
Market cap4mUSD
Jul 10, Last price
5.75USD
1D
0.35%
1Q
-96.81%
IPO
-100.00%
Name
Paranovus Entertainment Technology Ltd
Chart & Performance
P/E
—
P/S
68.87
EPS
—
Div Yield, %
—
Shrs. gr., 5y
134.49%
Rev. gr., 5y
-74.40%
Revenues
72k
-98.91%
Net income
-8m
L-22.05%
CFO
-3m
L-79.63%
Dividend
Aug 07, 20200.015 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating both domestically in the People's Republic of China and across international markets, Happiness Development Group Limited (formerly Happiness Biotech Group Limited until October 2022) specializes in the research, creation, and sale of nutraceuticals and dietary supplements. Their extensive product catalog includes traditional Chinese medicinal extracts like lucidum spore powders, cordyceps mycelia, Ejiao, and American ginseng, alongside a variety of other herbal and animal extracts, vitamins, minerals, and amino acids. Beyond health-focused products, the company provides diverse service offerings. Under its Happy Buy platform, it delivers e-commerce agency and marketing services to small and medium-sized businesses, as well as offering e-commerce solutions, digital information, and advertising services to online retailers and manufacturers. Furthermore, through the Taochejun platform, the group facilitates secure vehicle transactions, automobile procurement, and financial support for car manufacturers. Happiness-branded goods are distributed via a broad network of channels, including independent distributors, major pharmacy chains, shopping centers, and supermarkets. Founded in 2004, the company is headquartered in Nanping, PRC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||